AMO Pharma Initiates P-II REACH-CDM study of AMO-02 (tideglusib) to treat Congenital Myotonic Dystrophy

Shots: The P-II REACH-CDM evaluate the efficacy and safety of AMO-02 (tideglusib) in 56 patients to treat congenital Myotonic Dystrophy in the U.S and Canada with additional sites in Australia, New Zealand, and other countries to be added seeking local approvals The REACH-CDM study was designed on the basis of positive P-II data results which …

AMO Pharma Initiates P-II REACH-CDM study of AMO-02 (tideglusib) to treat Congenital Myotonic Dystrophy Read More »